MDxHealth SA - Ordinary Shares (MDXH)

August 14, 2026 — Investor attention continues to focus on microcap stocks, small-cap earnings, artificial intelligence, cybersecurity, biotechnology, Alzheimer’s drug development and high-growth technology, with Kartoon Studios (NYSE: TOON), Cycurion (NASDAQ: CYCU), SurgePays (NASDAQ: SURG), MDxHealth (NASDAQ: MDXH) and IGC Pharma (NYSE: IGC) presenting several developing catalysts.

August 14, 2026 - VivoSim Labs, Inc. (NASDAQ: VIVS) is emerging at the intersection of artificial intelligence, biotechnology, drug development, 3D human tissue models and New Approach Methodologies (NAMs) as pharmaceutical companies face increasing pressure to identify costly drug toxicity problems earlier in the development process.

Aug. 14, 2026 — Kartoon Studios, Inc. (NYSE: TOON), a global children’s and family entertainment company, reported second-quarter 2026 financial results while outlining a strategic transformation centered on the ownership, development and commercialization of high-value intellectual property.

Second quarter revenue growth of 16% to $27.2 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET

Company to Host Conference Call with Live Q&A, August 13, 2026, at 4:30pm ET / 22:30 CET

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency

IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated June 30, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial

Mdxhealth Reports Q1-2026 Results

Mdxhealth to Release First Quarter 2026 Financial Results on May 13

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025

Mdxhealth to Release Third Quarter 2025 Financial Resultson November 12

Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May.

Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET

Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET

Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET